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Abstract
Background: X-chromosomal inheritance patterns and generally rare occurrence of Fabry disease (FD) account
for mono-mutational hemizygous male and heterozygous female patients. Female mutation carriers are usually
clinically much less severely affected, which has been explained by a suggested mosaicism in cell phenotype due
to random allele shutdown. However, clinical evidence is scarce and potential additional effects in female gene
carriers, which might account for specific clinical characteristics such as less severe chronic kidney disease, are yet
unknown.
Case presentation: This article reports on a 45 year old female patient carrying the two alpha-galactosidase A
gene mutations c.416A > G, p.N139S in exon 3 and c.708G > C, p.W236C in exon 5, but still showing only mild
organ manifestations.
Conclusion: This current case highlights the importance of careful clinical characterization in patients with Fabry
disease, who may show additional rare constellations and, therefore, are in need of personalized medicine. The
impact of potential additional protective effects exceeding the presence of a non-pathogenic GLA allele in female
gene carriers requires further investigation.
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Background
Anderson-Fabry disease (FD) is a rare, X-chromosomal
inherited lysosomal storage disorder resulting from cur-
rently over 800 known pathogenic alpha-galactosidase A
gene (GLA) mutations [1, 2]. Recent focus has been set
on understanding mutation-specific clinical characteris-
tics and outcome, which might eventually lead to a clin-
ically relevant sub-classification of FD, such as into
classical, non-classical, “late onset” and/or organ-specific
variants [3–6]. While most X-linked diseases only cause
phenotypical manifestations in male patients with females
usually being completely unaffected carriers [7, 8], FD-
females may develop manifestations to a specific extent,
which are usually much less severe in terms of clinical
symptoms compared to respective men [2, 9, 10]. This is
attributed to the fact that women nearly always present a
heterozygous GLA genotype including one further, non-
pathologically affected allele. However, the definite under-
lying mechanisms ultimately leading to somewhat less
morbidity in female FD patients are still under debate. A
potential impact of skewed X-inactivation has been sup-
posed central, leading to random transcriptional silencing
of one of both X‐chromosomes in every cell, eventually
leading to the typical findings of female genetic mo-
saicism [8, 11, 12]. Due to the marked variance of FD
regarding clinical symptoms, there is high interest to
characterize the impact of genotypes in order to
embrace patients individualized additive therapeutic
needs aside from enzyme replacement therapy (ERT)
and improve mechanistic knowledge regarding
genotype-phenotype pathophysiology.
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Methods
All patients attending the Fabry Center for Interdis-
ciplinary Therapy (FAZIT) Wurzburg, Germany,
undergo a standardized comprehensive clinical, la-
boratory and imaging examination with special focus
on Fabry-related impairments and organ involvement.
Cardiac imaging modalities include standard two-
dimensional echocardiography, as well as speckle
tracking analysis, and cardiac magnetic resonance
tomography (MRI), both beneficial for indirect quanti-
fication of intramural fibrosis as prominently seen in
advanced Fabry cardiomyopathy [13–15]. Investiga-
tions also include a thorough investigation of the kid-
neys including biopsy if suitable, central and
peripheral nervous system including brain MRI, skin
biopsy, and assessment of sweating capacity, and psy-
chic factors, including assessment of quality of life
using SF-36.
Case presentation
In late 2015, a 45-year-old female patient with genet-
ically proven FD approached FAZIT for specialized
clinical evaluation and therapy induction. Molecular
gene analysis revealed the atypical situation of a het-
erozygous female patient carrying two different haplo-
type variants – c.416A > G, p.N139S in exon 3 and
c.708G > C, p.W236C in exon 5, one on each X-
chromosomal allele – which both have previously
been described as potentially pathogenic [16, 17]. Due
to the low frequency of pathogenic GLA mutations in
the population, comparable respective cases are ex-
tremely rare. The initial suspicion for FD in this
index patient was raised during a routine ophthal-
mologist checkup leading to the discovery of Fabry-
specific depositions in her cornea at young age of six
years. Later on, it was revealed that not only her
mother, but also her brother are both affected by the same
mutational variant (c.708G > C, p.W236C in exon 5),
which was in both relatives clinically related to Fabry-
associated acral pain, myocardial hypertrophy, and renal
Table 1 General- and Fabry-associated characteristics, bio-
markers, renal function and quality of life of the index patient
Variables Index patient Reference values
Demographics
Age at first visit (years) 44
Body-mass-index (kg/m2) 20.7
Biomarkers
Lyso-Gb3 (ng/ml) 30.2 <0.9
α-Gal A (nmol/min/mg protein) 0.26 0.4–1.0
NT-proBNP (pg/ml) 325 0–153 (age-
dependent)
hs-TnT (pg/ml) <5 0–14
Renal
Serum-Creatinine (mg/dl) 0.80 0–0.95
Cystatin C (mg/l) 0.76 0.61–0.95
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Abbreviations: α-Gal Aalpha-galactosidase A enzyme activity, ACEi
angiotensin-converting-enzyme inhibitor, ARBs Angiotensin II receptor
antagonists, ASA/OAC acetylsalicylic acid/oral anticoagulation therapy, ERT
enzyme replacement therapy, GFR glomerular filtration rate, hs-TnT
high-sensitive troponin T, NT-proBNP N-terminal pro-brain natriuretic peptide
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dysfunction. In addition, the index patient’s brother suf-
fered from young-aged stroke at age 45 years and now re-
ceives hemodialysis due to end-stage chronic kidney
disease. Her grandfather from maternal site is anticipated
to have been affected by FD, suffering from fatal end-stage
kidney disease at his early forties. Unfortunately, the index
patient’s 74 years old father refused to undergo genetic
analysis. As the index patient never subjectively suffered
from any health problems, neither doctors were consulted
nor medication taken until the event of young-aged
cryptogenic stroke at the age of 44 years. As a result of
stroke, she attended FAZIT for clinical examination and
initiation of life-time ERT.
At FAZIT she denied any acral pain or gastro-
intestinal claims besides of frequent diarrhea. Sweating
capacity was reported mildly reduced, but only attracted
her attention in hot summer months (Table 1). Alpha-
galactosidase A (α-Gal A) enzyme activity was measured
reduced (0.26 nmol/min/mg protein in leucocytes; refer-
ence: 0.4–1.0) and plasma lyso-Gb3 was elevated
(30.2 ng/ml; reference: ≤0.9). The body-mass-index
(20.5 kg/m2), resting blood pressure (100/82 mmHg)
and heart rate (80 bpm) were all in normal ranges, with
sinus rhythm and no signs of cardiac hypertrophy or is-
chemia in neither resting, nor exercise electrocardio-
grams (ECG). (Table 2) Physical capacity in exercise
ECG was sufficient, reaching a maximal heart rate of
133 bpm, 75 % of the age-predicted optimum of
176 bpm at 125 W. No spontaneous cardiac arrhythmia
was detectable in Holter monitoring, or evocable in ex-
ercise stress test. The cardiac biomarker high-sensitive
troponin T was inconspicuous for cardiac involvement
(<5 pg/ml; reference: 0–14). N-terminal pro-brain natri-
uretic peptide was slightly elevated (325 pg/ml; refer-
ence: <125), which might be a hint on an early stage
cardiac involvement. This suspicion from blood bio-
markers was supported by findings in standard cardiac
imaging, revealing borderline septal and posterior wall
thickness of 11 mm and a visually determined concentric
left ventricular (LV) hypertrophy with prominent papil-
lary muscles but physiologically preserved LV ejection
fraction (68 %) in echocardiography. The normalized LV
mass was 66.7 g/m2, normalized end-systolic volume
26.0 ml/m2, normalized end-diastolic volume 75.9 ml/
m2, normalized stroke volume 49.9 ml/m2, and the car-
diac index 3.19 l/min/m2 in cardiac MRI with minimal
intramural left ventricular late gadolinium enhancement,
as seen in early stage Fabry cardiomyopathy (Fig. 1a/b)
[15, 18]. In order to more evidently investigate the pos-
sible presence of mild fibrotic scar tissue, two-
dimensional echo speckle tracking was performed,
allowing inferences on myocardial muscle rigidity and
stiffness in an 18 segment model. The result revealed a
mild pathologic peak systolic strain in the posterior-




Systolic blood pressure (mmHg) 115
Diastolic blood pressure (mmHg) 75
Heart rate (bpm) 68
Cardiac stress test
maximal heart rate (bpm) 133
















Speckle tracking strain rate [S−1]
global strain rate −1.50
basal strain rate −1.24
mid strain rate −1.25
apical strain rate −2.17
septal strain rate −1.61
lateral strain rate −1.49
Cardiac MRI
LGE (yes/no) none
normalized LVM (g/m2) 66.7
normalized ESV (ml/m2) 26.0
normalized EDV (ml/m2) 75.9
normalized SV (ml/m2) 49.9
CI (l/min/m2) 3.19
LVEF (%) 65.7
Abbreviations: DT deceleration time, IVSd interventricular septum thickness in
end-diastole, LVEF left ventricular ejection fraction in %, LVMI left ventricular
mass index in echocardiography, LVPWD left ventricular posterior wall
thickness in end-diastole, normalized EDV normalized end-diastolic volume in
cardiac MRI, normalized ESV normalized end-systolic volume in cardiac MRI,
normalized LVM normalized left ventricular mass in cardiac MRI, normalized SV
normalized stroke volume in cardiac MRI
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lateral and anterior-lateral wall segments visualized by
speckle tracking bull’s eye (Fig. 1c) hinting on a very
early stage of cardiomyopathy [14]. Renal function
was completely preserved, with a 99-Technetium
DTPA clearance of 90 ml/min, a serum-creatinine of
0.80 mg/dl (reference: 0–0.95), and cystatin-c of
0.76 mg/l (reference: 0.61–0.95), with no prove of
pathologic proteinuria in spot or collecting urine.
Brain MRI revealed residual lesions due to the previ-
ously suffered stroke (Fig. 1d/e), Health related
quality of life was accessed by the SF-36 question-
naires and revealed reduced physical (41.61 out of
100) and mental component summary scores (35.17
out of 100) reflecting both somatic and mental impact
on the index patient’s subjective well-being.
By rules of genetic penetrance, in this particular case
the index patient conducts one of her pathogenic GLA
alleles to all of her biological descendants. Thus both of
her children, an 11 year old daughter and her 8 year old
son underwent genetic analysis for FD (Centogene AG,
Fig. 1 Index patient’s imaging features of cardiac a-c and brain d-e involvement at FAZIT baseline visit. Please note that morphologic and late gadolinium
enhancement cardiac MRI a-b reveals mild hypertrophy and marginal fibrotic scar tissue with only minimal intramural late gadolinium enhancement
detectable. In two-dimensional speckle tracking c peak systolic strain is mildly reduced, visualizing in loco typico early stage Fabry cardiomyopathy in the
posterior-lateral and antero-lateral walls (bull’s eye method). Brain MRI d-e shows residual lesions (encircled) due to previously suffered cryptogenic stroke
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Rostock, Germany), both presenting the c.708G > C,
p.W236C mutation in exon 5. α-Gal A enzyme activity
was reduced in her daughter (0.20 nmol/min/mg protein
in leucocytes) and highly reduced in the index patient’s
son (0.03 nmol/min/mg protein in leucocytes). Lyso-
Gb3 was 8.1 ng/ml in the index patient’s daughter and
not determined in her son. Interestingly, her son already
claims about stinging pain occurring in situations of
bodily stress and during infections even though he is at
very young age.
Female mutation carriers usually present milder pheno-
types than comparable males, which might be explained
due to compensatory effects of the second, non-
pathologically affected allele. In rare cases of homozygous
female patients classical FD is to be expected. In this regard,
Rodríguez-Marí and colleagues reported about a young fe-
male patient, who was found homozygous for the Q279R
GLA mutation and presented a classics Fabry-phenotype
with cardiac and neurological organ involvement, reduced
α-Gal A activity, Fabry-associated angiokeratoma, a reduced
sweating capacity and acral pain, which started at young age
of 8 years [19]. In contrast, all three female homozygous pa-
tients (p.Arg118Cys variant) published by Susana Ferreira
and colleagues did not develop a classical Fabry phenotype,
highlighting the impact of mutation-specific factors in FD
[20]. However, contradictory to both mentioned reports, the
index patient of the current study was found homozygous
with not one and the same, but two different GLA muta-
tions in each of her alleles. Regarding our index patient,
family pedigree, laboratory data, and clinical manifestations
give a mixed picture regarding disease patterns. While
young-aged stroke gives evidence for neurological manifes-
tations, further organ involvement was minimal with only
very mild cardiac and no renal impairments detectable.
Comparing her clinical course to her brothers’, much less
severe manifestations were found. This could indicate that
there might not be an additive effect of two independent
pathogenic GLA alleles, questioning the anticipated clinical
impact of skewed X-inactivation leading to silence of the
index patient’s second pathogenic allele. It might instead be
speculated that there could be so far unknown additional
modifying effects in females, preventing severe clinical
courses including e.g. chronic renal disease. These assump-
tions remain limited due to the scarce comprehensive data
about p.N139S available in literature, discussing this re-
spectively novel mutation being of pathogenic impact [17].
However, long-term results remain to be evaluated in order
to judge on clinical severity and outcome over time.
Both of the index patient’s children are likely to de-
velop organ involvement as seen in their biological rela-
tives. As therapeutic effects of ERT have been reported
to be most beneficial when started before organ injury is
detectable [21, 22], it is to be discussed whether and
when the index patient’s children should start receiving
ERT, particularly in the light of the high prevalence of
young-aged stroke in the family pedigree.
Conclusion
In summary, this current case highlights the importance
of careful clinical characterization in patients with Fabry
disease, who may show additional uncommon constella-
tions and are thus in need of personalized medicine. The
impact of potential additional protective effects exceed-
ing the presence of a non-pathogenic GLA allele in fe-
male gene carriers require further investigation.
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